Evonik, OPX Biotechnologies to jointly develop bio-based chemicals


Evonik Industries and OPX Biotechnologies (OPXBIO) have signed an agreement to jointly develop certain bio-based specialty chemicals.

"The agreement will also enable OPXBIO to market bio-based products resulting from the Evonik partnership."

The joint-development agreement, which was signed on 3 May 2013, necessitates OPXBIO to employ its patented Efficiency Directed Genome Engineering (EDGE) technology to develop the bio-processes.

Creavis Science-to-Business Center Biotechnology vice president Dr. Thomas Haas said: "There's a growing market demand for more sustainable products and processes, and OPXBIO is an excellent partner to help us meet that demand because their technology can create high-value, bio-based chemicals quickly and cost-effectively."

The agreement will also enable OPXBIO to market bio-based products resulting from the Evonik partnership.

OPX Biotechnologies president and CEO Charles Eggert said: "The bio-process we're developing has the potential to create economic and sustainable versions of products we use in our everyday lives."

Creavis is the strategic research and development unit of Evonik.

Energy